Treatment of the cisplatin-resistant NSCLC sublines with low-dose ATRA (5 μM) significantly depleted the presence of the ALDH1+ve subpopulation across all resistant sublines. The gene discussed is ALDH1A1; the disease is non-small cell lung carcinoma.